Imatinib (GleevecTM), a small molecule ATP-competitive inhibitor of BCR-Abl, is an effective front-line treatment for CML and has established the concept of targeted kinase inhibition as a viable strategy for cancer therapy [2]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.